tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

OKYO Stock Latest News

OKYO Pharma Advances Urcosimod Clinical Trials for Neuropathic Corneal Pain
Company AnnouncementsOKYO Pharma Advances Urcosimod Clinical Trials for Neuropathic Corneal Pain
5d ago
6K
OKYO
Okyo Pharma announces plans for next stage of development for urcosimod
PremiumThe Fly
Okyo Pharma announces plans for next stage of development for urcosimod
5d ago
OKYO
Okyo Pharma initiated with a Buy at Lucid Capital
PremiumThe Fly
Okyo Pharma initiated with a Buy at Lucid Capital
2M ago
OKYO
OKYO Pharma Secures $1.9 Million to Boost Urcosimod Development
PremiumCompany Announcements
OKYO Pharma Secures $1.9 Million to Boost Urcosimod Development
2M ago
6K
OKYO
Okyo Pharma receives $1.9M in non-dilutive funding
PremiumThe Fly
Okyo Pharma receives $1.9M in non-dilutive funding
2M ago
OKYO
Positive Buy Rating for OKYO Pharma Driven by Promising Phase 2 Trial Results and FDA Fast Track Designation
PremiumRatingsPositive Buy Rating for OKYO Pharma Driven by Promising Phase 2 Trial Results and FDA Fast Track Designation
2M ago
OKYO
OKYO Pharma Reports Promising Phase 2 Results for Urcosimod in Treating Neuropathic Corneal Pain
Premium
Company Announcements
OKYO Pharma Reports Promising Phase 2 Results for Urcosimod in Treating Neuropathic Corneal Pain
2M ago
6K
OKYO
Okyo Pharma reports Phase 2 clinical trial results for urcosimod
Premium
The Fly
Okyo Pharma reports Phase 2 clinical trial results for urcosimod
2M ago
OKYO
OKYO Pharma CEO to Present Urcosimod Development at Bio International Convention
PremiumCompany Announcements
OKYO Pharma CEO to Present Urcosimod Development at Bio International Convention
4M ago
6K
OKYO
OKYO Pharma CEO to Present at Boston Drug Discovery Summit
PremiumCompany Announcements
OKYO Pharma CEO to Present at Boston Drug Discovery Summit
4M ago
6K
OKYO
OKYO Pharma’s Urcosimod Receives FDA Fast Track Designation for Neuropathic Corneal Pain
PremiumCompany Announcements
OKYO Pharma’s Urcosimod Receives FDA Fast Track Designation for Neuropathic Corneal Pain
5M ago
6K
OKYO
Okyo Pharma announces FDA granted FTD to urcosimod
PremiumThe Fly
Okyo Pharma announces FDA granted FTD to urcosimod
5M ago
OKYO
Promising Developments in OKYO Pharma’s Urcosimod Program Drive Buy Rating and $7 Price Target
PremiumRatingsPromising Developments in OKYO Pharma’s Urcosimod Program Drive Buy Rating and $7 Price Target
5M ago
OKYO
OKYO Pharma Accelerates Urcosimod Development for Neuropathic Corneal Pain
Premium
Company Announcements
OKYO Pharma Accelerates Urcosimod Development for Neuropathic Corneal Pain
5M ago
6K
OKYO
Okyo Pharma announces plans to accelerate development of urcosimod
Premium
The Fly
Okyo Pharma announces plans to accelerate development of urcosimod
5M ago
OKYO
OKYO Pharma Achieves Key Stability Milestone for Urcosimod
PremiumCompany Announcements
OKYO Pharma Achieves Key Stability Milestone for Urcosimod
6M ago
6K
OKYO
Okyo Pharma announces data on long-term stability of urcosimod
PremiumThe Fly
Okyo Pharma announces data on long-term stability of urcosimod
6M ago
OKYO
OKYO Pharma Seeks FDA Fast Track for Urcosimod in Treating Neuropathic Corneal Pain
PremiumCompany Announcements
OKYO Pharma Seeks FDA Fast Track for Urcosimod in Treating Neuropathic Corneal Pain
7M ago
6K
OKYO
Okyo Pharma files for FTD with FDA for urcosimod
PremiumThe Fly
Okyo Pharma files for FTD with FDA for urcosimod
7M ago
OKYO
Buy Recommendation for OKYO Pharma Driven by Promising Urcosimod Efficacy and Market Potential
PremiumRatingsBuy Recommendation for OKYO Pharma Driven by Promising Urcosimod Efficacy and Market Potential
7M ago
OKYO
OKYO Pharma’s Lead Asset OK-101 Receives USAN as Urcosimod
Premium
Company Announcements
OKYO Pharma’s Lead Asset OK-101 Receives USAN as Urcosimod
8M ago
6K
OKYO
Okyo Pharma announces OK-101 officially assigned USAN, urcosimod
Premium
The Fly
Okyo Pharma announces OK-101 officially assigned USAN, urcosimod
8M ago
OKYO

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >